Clinical Trial Update: Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical trial evaluating crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN